Stockscreener 앱 받기
64.01
1.30%
0.82
전일 마감가:
$63.19
열려 있는:
$63.29
하루 거래량:
1.72M
Relative Volume:
0.90
시가총액:
$7.83B
수익:
$18.47M
순이익/손실:
$-589.53M
주가수익비율:
-12.17
EPS:
-5.26
순현금흐름:
$-399.80M
1주 성능:
+0.36%
1개월 성능:
+1.43%
6개월 성능:
+72.16%
1년 성능:
+28.17%
1일 변동 폭
$63.15
$65.98
1주일 범위
$62.13
$65.98
52주 변동 폭
$29.31
$70.98
Cytokinetics Inc Stock (CYTK) Company Profile
명칭
Cytokinetics Inc
전화
(650) 624-3000
주소
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
CYTK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
64.01 | 7.73B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-18 | 업그레이드 | Goldman | Neutral → Buy |
| 2025-07-30 | 재개 | Raymond James | Mkt Perform |
| 2025-04-24 | 개시 | Barclays | Overweight |
| 2025-02-07 | 개시 | Citigroup | Buy |
| 2025-01-22 | 개시 | Stifel | Buy |
| 2024-11-08 | 개시 | RBC Capital Mkts | Outperform |
| 2024-08-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-01-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-01-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | 개시 | Goldman | Buy |
| 2023-11-07 | 개시 | B. Riley Securities | Buy |
| 2023-08-15 | 개시 | SVB Securities | Outperform |
| 2023-02-17 | 개시 | BofA Securities | Neutral |
| 2022-12-23 | 재확인 | Needham | Buy |
| 2022-12-20 | 개시 | Truist | Buy |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-01-28 | 개시 | Goldman | Buy |
| 2021-12-22 | 개시 | Oppenheimer | Outperform |
| 2021-12-10 | 개시 | JP Morgan | Overweight |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-03-12 | 개시 | Wolfe Research | Outperform |
| 2021-02-18 | 개시 | Barclays | Overweight |
| 2021-01-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-29 | 개시 | Goldman | Neutral |
| 2020-07-10 | 개시 | Raymond James | Strong Buy |
| 2020-05-05 | 개시 | Mizuho | Buy |
| 2020-04-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-10 | 재개 | Morgan Stanley | Equal-Weight |
| 2017-11-22 | 재확인 | Morgan Stanley | Overweight |
| 2017-11-22 | 다운그레이드 | Needham | Strong Buy → Buy |
| 2017-11-21 | 재확인 | H.C. Wainwright | Buy |
| 2017-07-31 | 개시 | Morgan Stanley | Overweight |
| 2017-03-08 | 개시 | Rodman & Renshaw | Buy |
| 2017-02-06 | 업그레이드 | Needham | Buy → Strong Buy |
| 2016-12-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-07-28 | 재확인 | Needham | Buy |
| 2015-11-10 | 재확인 | FBR Capital | Outperform |
| 2015-11-09 | 재확인 | ROTH Capital | Buy |
| 2015-07-24 | 재확인 | MLV & Co | Buy |
| 2014-12-31 | 재확인 | ROTH Capital | Buy |
| 2014-11-04 | 업그레이드 | MLV & Co | Hold → Buy |
| 2014-04-28 | 재확인 | Needham | Buy |
모두보기
Cytokinetics Inc 주식(CYTK)의 최신 뉴스
Assessing Whether Cytokinetics (CYTK) Looks Undervalued After Recent Share Price Momentum - Yahoo Finance
How MYQORZO’s REMS‑Restricted U.S. Launch Will Impact Cytokinetics (CYTK) Investors - Yahoo Finance
Truist Securities reiterates Buy rating on Cytokinetics stock at $84 target - Investing.com Canada
Cytokinetics launches first product, Myqorzo - The Pharma Letter
Analyst Upgrade: What is the long term forecast for Cytokinetics Incorporated stock2025 Price Momentum & Community Consensus Trade Signals - baoquankhu1.vn
Cytokinetics (CYTK) Launches HCM Awareness Campaign with Olympic Star - GuruFocus
CYTK: Cytokinetics Launches Myqorzo in the U.S. for Heart Condition - GuruFocus
Olympian Sydney McLaughlin-Levrone on hypertrophic cardiomyopathy at home - Stock Titan
Cytokinetics Announces U.S. Launch of MYQORZO™ (aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy - Quiver Quantitative
New heart drug MYQORZO reaches U.S. patients, but with strict safety rules - Stock Titan
US FDA caps 2025 with December high of 27 drug approvals - BioWorld MedTech
Cytokinetics, Incorporated (CYTK) Stock Analysis: Uncovering a 41% Potential Upside in the Biotech Sector - directorstalkinterviews.com
RBC Capital Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $95 - 富途资讯
Cytokinetics Board Faces Claims of Breach of Fiduciary Duty as Stock Plummets - Intellectia AI
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Investors to Connect - ACCESS Newswire
The Law Offices of Frank R. Cruz Announces Investigation of Cytokinetics, Incorporated (CYTK) on Behalf of Investors - marketscreener.com
Bull Bear: What are HSPOs earnings expectationsLayoff News & Capital Efficiency Focused Strategies - baoquankhu1.vn
RBC Capital Reiterates Outperform Rating for Cytokinetics (CYTK) - GuruFocus
Key facts: B. Riley Raises Cytokinetics Price Target to $108; Stock Options Issued - TradingView
Cytokinetics (CYTK) Sees Positive Analyst Rating Updates: Price Target Raised | CYTK Stock News - GuruFocus
Royal Bank Of Canada Reiterates "Outperform" Rating for Cytokinetics (NASDAQ:CYTK) - MarketBeat
Brokers Issue Forecasts for Cytokinetics FY2026 Earnings - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Cytokinetics announces inducement grants under Nasdaq Listing Rule - marketscreener.com
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule - TradingView
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Cytokinetics (NASDAQ:CYTK) Given New $74.00 Price Target at JPMorgan Chase & Co. - MarketBeat
CYTK: JP Morgan Raises Price Target, Maintains Overweight Rating - GuruFocus
What makes Cytokinetics Incorporated stock attractive to growth fundsMarket Activity Report & Community Trade Idea Sharing - bollywoodhelpline.com
Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Investors to Inquire about Securities Investigation - ACCESS Newswire
Gainers Report: Can Cytokinetics Incorporated reach all time highs this year - baoquankhu1.vn
Should you avoid Cytokinetics Incorporated stock right now2025 Risk Factors & Stepwise Trade Signal Guides - baoquankhu1.vn
Profit Recap: Is TCBX in accumulation or distribution phaseWeekly Market Summary & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Spinal Muscular Atrophy Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Genentech Inc, Chugai Pharma, Cytokinetics Inc., Ionis Pharma, Genzyme - Barchart.com
Orsini Selected as Specialty Pharmacy Partner for Cytokinetics's MYQORZO™ (aficamten) - PR Newswire
SG Americas Securities LLC Purchases 43,349 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics, Incorporated (CYTK) Stock Analysis: A Biotech With 41% Upside Potential - DirectorsTalk Interviews
Cytokinetics, Incorporated (NASDAQ:CYTK) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
FDA approves seven NMEs in December - biocentury.com
Jefferies raises Cytokinetics stock price target to $90 on ACACIA study - Investing.com Canada
How Cytokinetics Incorporated stock trades before earnings2025 Volume Leaders & Momentum Based Trading Ideas - ulpravda.ru
Is Cytokinetics Incorporated stock attractive for long term wealth building2025 Institutional Moves & High Accuracy Trade Alerts - ulpravda.ru
Is Cytokinetics Incorporated stock attractive for hedge fundsQuarterly Portfolio Summary & Safe Entry Trade Reports - ulpravda.ru
Is Cytokinetics Incorporated stock a good choice for value investorsWeekly Investment Report & Step-by-Step Swing Trade Plans - ulpravda.ru
Is Cytokinetics Incorporated (KK3A) stock a top pick for value investorsQuarterly Trade Summary & Daily Growth Stock Investment Tips - ulpravda.ru
Can Cytokinetics Incorporated stock deliver consistent earnings growthPortfolio Value Summary & Risk Controlled Stock Alerts - ulpravda.ru
Risk Analysis: Can Cytokinetics Incorporated stock reach $100 price targetMarket Performance Recap & Expert Curated Trade Ideas - ulpravda.ru
Can Cytokinetics Incorporated stock maintain growth trajectoryInsider Selling & Daily Profit Focused Screening - ulpravda.ru
Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore ... - bdtonline.com
Important Notice to Long-Term Shareholders of Cytokinetics, - GlobeNewswire
Cytokinetics Inc (CYTK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.09%
0.48%
자본화:
|
볼륨(24시간):